Product: VeriStrat
-
Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer
-
Integration of the Clin-ToF into the VeriStrat clinical testing workflow to generate serum protein profiles for prognosis and therapeutic guidance in NSCLC
-
Second‐line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUXLung 8 [LL8]): analysis of tumour and serum biomarkers and long‐term responders
-
Evaluation of Pretreatment Serum Tests for Nivolumab Benefit in Patients with Non-Small Cell Lung Cancer
-
Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC
-
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
-
Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung
-
Evaluation of VeriStrat, a serum proteomic test, in the randomized, open‐label, Phase 3 LUX‐Lung 8 (LL8) trial of afatinib (A) versus erlotinib (E) for the second‐line treatment of advanced squamous cell carcinoma (SCC) of the lung
-
Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial
-
Retrospective Evaluation of the Randomized, Phase 3 MARQUEE Trial of Tivantinib (T) + Erlotinib (E) vs Placebo (P) + Erlotinib (E) Using VeriStrat in Patients With Previously Treated Non-Squamous NSCLC